156 related articles for article (PubMed ID: 29468454)
1. Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC).
Nakayama T; Sagara Y; Takashima T; Matsunami N; Masuda N; Miyoshi Y; Taguchi T; Aono T; Ito T; Kagimura T; Noguchi S
Cancer Chemother Pharmacol; 2018 Apr; 81(4):755-762. PubMed ID: 29468454
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: Results of the UNICANCER CARMINA 02 French trial (UCBG 0609).
Lerebours F; Rivera S; Mouret-Reynier MA; Alran S; Venat-Bouvet L; Kerbrat P; Salmon R; Becette V; Bourgier C; Cherel P; Boussion V; Balleyguier C; Thibault F; Lavau-Denes S; Nabholz JM; Sigal B; Trassard M; Mathieu MC; Martin AL; Lemonnier J; Mouret-Fourme E
Cancer; 2016 Oct; 122(19):3032-40. PubMed ID: 27315583
[TBL] [Abstract][Full Text] [Related]
3. [Safety and compliance with UFT (tegafur and uracil) alone and in combination with hormone therapy in patients with breast cancer].
Taguchi T; Noguchi S
Gan To Kagaku Ryoho; 2009 Sep; 36(9):1465-74. PubMed ID: 19755814
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
Tanaka S; Iwamoto M; Kimura K; Takahashi Y; Fujioka H; Sato N; Terasawa R; Kawaguchi K; Ikari A; Tominaga T; Maezawa S; Umezaki N; Matsuda J; Uchiyama K
Anticancer Res; 2016 Dec; 36(12):6505-6509. PubMed ID: 27919974
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial.
Masuda N; Sagara Y; Kinoshita T; Iwata H; Nakamura S; Yanagita Y; Nishimura R; Iwase H; Kamigaki S; Takei H; Noguchi S
Lancet Oncol; 2012 Apr; 13(4):345-52. PubMed ID: 22265697
[TBL] [Abstract][Full Text] [Related]
6. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
[TBL] [Abstract][Full Text] [Related]
7. Postoperative chemo-endocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Nishinihon Cooperative Study Group of Adjuvant Therapy for Breast Cancer.
Sugimachi K; Maehara Y; Akazawa K; Nomura Y; Eida K; Ogawa M; Konaga E; Tanaka N; Toge T; Dohi K; Noda S; Maeda M; Monden Y
Breast Cancer Res Treat; 1999 Jul; 56(2):113-24. PubMed ID: 10573104
[TBL] [Abstract][Full Text] [Related]
8. Postoperative adjuvant therapy with tamoxifen, tegafur plus uracil, or both in women with node-negative breast cancer: a pooled analysis of six randomized controlled trials.
Noguchi S; Koyama H; Uchino J; Abe R; Miura S; Sugimachi K; Akazawa K; Abe O
J Clin Oncol; 2005 Apr; 23(10):2172-84. PubMed ID: 15800310
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of oral tegafur-uracil (UFT) as adjuvant therapy as compared with classical cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in early breast cancer: a pooled analysis of two randomized controlled trials (N.SAS-BC 01 trial and CUBC trial).
Ohashi Y; Watanabe T; Sano M; Koyama H; Inaji H; Suzuki T
Breast Cancer Res Treat; 2010 Feb; 119(3):633-41. PubMed ID: 19936917
[TBL] [Abstract][Full Text] [Related]
10. A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer.
Hortobagyi GN; Heim W; Hutchins L; Rivera E; Mason B; Booser DJ; Kirshner J
Cancer; 2010 Mar; 116(6):1440-5. PubMed ID: 20091835
[TBL] [Abstract][Full Text] [Related]
11. Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR
Hurvitz SA; Martin M; Press MF; Chan D; Fernandez-Abad M; Petru E; Rostorfer R; Guarneri V; Huang CS; Barriga S; Wijayawardana S; Brahmachary M; Ebert PJ; Hossain A; Liu J; Abel A; Aggarwal A; Jansen VM; Slamon DJ
Clin Cancer Res; 2020 Feb; 26(3):566-580. PubMed ID: 31615937
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial.
Smith IE; Dowsett M; Ebbs SR; Dixon JM; Skene A; Blohmer JU; Ashley SE; Francis S; Boeddinghaus I; Walsh G;
J Clin Oncol; 2005 Aug; 23(22):5108-16. PubMed ID: 15998903
[TBL] [Abstract][Full Text] [Related]
13. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer.
Hortobagyi GN; Young RR; Karwal M; Ibrahim NK; Hermann R; Murray JL; Watkins SP; Gore I
Cancer; 2010 May; 116(10):2301-6. PubMed ID: 20225231
[TBL] [Abstract][Full Text] [Related]
14. Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Cristofanilli M; Valero V; Mangalik A; Royce M; Rabinowitz I; Arena FP; Kroener JF; Curcio E; Watkins C; Bacus S; Cora EM; Anderson E; Magill PJ
Clin Cancer Res; 2010 Mar; 16(6):1904-14. PubMed ID: 20215537
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Wu W; Deng H; Rao N; You N; Yang Y; Cao M; Liu J
Trials; 2017 Oct; 18(1):497. PubMed ID: 29070044
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
[TBL] [Abstract][Full Text] [Related]
17. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
18. A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial.
Matsuda C; Ishiguro M; Teramukai S; Kajiwara Y; Fujii S; Kinugasa Y; Nakamoto Y; Kotake M; Sakamoto Y; Kurachi K; Maeda A; Komori K; Tomita N; Shimada Y; Takahashi K; Kotake K; Watanabe M; Mochizuki H; Nakagawa Y; Sugihara K;
Eur J Cancer; 2018 Jun; 96():54-63. PubMed ID: 29677641
[TBL] [Abstract][Full Text] [Related]
19. Uracil-Tegafur and Oral Leucovorin Combined With Bevacizumab in Elderly Patients (Aged ≥ 75 Years) With Metastatic Colorectal Cancer: A Multicenter, Phase II Trial (Joint Study of Bevacizumab, Oral Leucovorin, and Uracil-Tegafur in Elderly Patients [J-BLUE] Study).
Nishina T; Moriwaki T; Shimada M; Higashijima J; Sakai Y; Masuishi T; Ozeki M; Amagai K; Negoro Y; Indo S; Denda T; Sato M; Yamamoto Y; Nakajima G; Mizuta M; Takahashi I; Hiroshima Y; Ishida H; Maeba T; Hyodo I
Clin Colorectal Cancer; 2016 Sep; 15(3):236-42. PubMed ID: 26778644
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide augments the anti-tumor efficacy of uracil and tegafur by inhibiting dihydropyrimidine dehydrogenase.
Nio Y; Iguchi C; Kodama H; Itakura M; Hashimoto K; Koike M; Toga T; Maruyama R; Fukushima M
Oncol Rep; 2007 Jan; 17(1):153-9. PubMed ID: 17143493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
